nach oben

Cancer Immunology, Immunotherapy

Erschienen in:

01.03.2004 | Review

Exosome-based immunotherapy

verfasst von: Nathalie Chaput, Julien Taïeb, Noël E. C. Schartz, Fabrice André, Eric Angevin, Laurence Zitvogel

Erschienen in: Cancer Immunology, Immunotherapy | Ausgabe 3/2004

Einloggen, um Zugang zu erhalten

Abstract

Exosomes are small membrane vesicles originating from late endosomes and secreted by hematopoietic and epithelial cells in culture. Exosome proteic and lipid composition is unique and might shed some light into exosome biogenesis and function. Exosomes secreted from professional antigen-presenting cells (i.e., B lymphocytes and dendritic cells) are enriched in MHC class I and II complexes, costimulatory molecules, and hsp70–90 chaperones, and have therefore been more extensively studied for their immunomodulatory capacities in vitro and in vivo. This review will present the main biological features pertaining to tumor or DC-derived exosomes, will emphasize their immunostimulatory function, and will discuss their implementation in cancer immunotherapy.

Denzer K, Kleijmeer MJ, Heijnen HF, Stoorvogel W, Geuze HJ (2000) Exosome: from internal vesicle of the multivesicular body to intercellular signaling device. J Cell Sci 113:3365–3374PubMed

Denzer K, van Eijk M, Kleijmeer MJ, Jakobson E, de Groot C, Geuze HJ (2000) Follicular dendritic cells carry MHC class II-expressing microvesicles at their surface. J Immunol 165:1259–1265PubMed

Quah B, O’Neill HC (2000) The application of dendritic cell-derived exosomes in tumour immunotherpy. Cancer Biother Radiopharm 15:185–194PubMed

André F, Schartz NE, Movassagh M, Flament C, Pautier P, Morice P, Pomel C, Lhomme C, Escudier B, Le Chevalier T, Tursz T, Amigorena S, Raposo G, Angevin E, Zitvogel L (2002) Malignant effusions and immunogenic tumor derived-exosomes. Lancet 360:295–305CrossRefPubMed

Zitvogel L, Regnault A, Lozier A, Wolfers J, Flament C, Tenza D, Ricciardi-Castagnoli P, Raposo G, Amigorena S (1998) Eradication of established murine tumors using a novel cell-free vaccine: dendritic cell-derived exosomes. Nat Med 4:594–600PubMed

Wolfers J, Lozier A, Raposo G, Regnault A, Thery C, Masurier C, Flament C, Pouzieux S, Faure F, Tursz T, Angevin E, Amigorena S, Zitvogel L (2001) Tumor-derived exosomes are a source of shared tumor rejection antigens for CTL cross-priming. Nat Med 7:297–303PubMed

Johnstone RM, Adam M, Hammond JR, Orr L, Turbide C (1987) Vesicle formation during reticulocyte maturation: association of plasma membrane activities with released vesicles (exosomes). J Biol Chem 262:9412–9420PubMed

Raposo G, Tenza D, Mecheri S, Peronet R, Bonnerot C, Desaymard C (1997) Accumulation of major histocompatibility complex class II molecules in mast cell secretory granules and their release upon degranulation. Mol Biol Cell 8:2631–2645PubMed

Escola JM, Kleijmeer MJ, Stoorvogel W, Griffith JM, Yoshie O, Geuze HJ (1998) Selective enrichment of tetraspan proteins on the internal vesicles of multivesicular endosomes and on exosomes secreted by human B-lymphocytes. J Biol Chem 273:20121–20127CrossRefPubMed

10.

Arnold PY, Mannie MD (1999) Vesicles bearing MHC class II molecules mediate transfer of antigen-presenting cells to CD4+ cells. Eur J Immunol 29:1363–1373CrossRefPubMed

11.

Heijnen IA, van Vugt MJ, Fanger NA, Graziano RF, de Wit TP, Hofhuis FM, Guyre PM, Capel PJ, Verbeek JS, van de Winkel JG (1996) Antigen targeting to myeloid-specific human Fc gamma RI/CD64 triggers enhanced antibody responses in transgenic mice. J Clin Investig 97:331–338

12.

Hess C, Sadallah S, Hefti A, Landmann R, Schifferli JA (1999) Ectosomes released by human neutrophils are specialized functional units. J Immunol 163:4564–4573PubMed

13.

Patel DM, Arnold PY, White GA, Nardella JP, Mannie MD (1999) Class II MHC/peptide complexes are released from APC and are acquired by T cell responders during specific antigen recognition. J Immunol 163:5201–5210PubMed

14.

Geminard C, Nault F, Johnstone RM, Vidal M (2001) Characteristics of the Interaction between Hsc70 and the transferrin receptor in exosomes released during reticulocyte maturation. J Biol Chem 276:9910–9916CrossRefPubMed

15.

Skokos D, Le Panse S, Villa I, Rousselle JC, Peronet R, David B, Namane A, Mecheri S (2001) Mast cell-dependent B and T lymphocyte activation is mediated by the secretion of immunologically active exosomes. J Immunol 166:868–876PubMed

16.

Thery C, Zitvogel L, Amigorena S (2002) Exosomes: composition, biogenesis and function. Nat Rev Immunol 2:569–579PubMed

17.

Yang S, Kittlesen D, Slingluff CL Jr, Vervaert CE, Seigler HF, Darrow TL (2000) Dendritic cells infected with a vaccinia vector carrying the human gp100 gene simultaneously present multiple specificities and elicit high-affinity T cells reactive to multiple epitopes and restricted by HLA-A2 and -A3. J Immunol 164(8):4204–4211PubMed

18.

Dhodapkar MV, Steinman RM, Krasovsky J, Munz C, Bhardwaj N (2001) Antigen-specific inhibition of effector T cell function in humans after injection of immature dendritic cells. J Exp Med 193:233–238PubMed

19.

Chaput N, André F, Schartz NEC, Escudier B, Turz T, Angevin E, Zitvogel L (2003) Proc Am Assoc Cancer Res 44:A4746

20.

Théry C, Duban L, Segura E, Véron P, Lantz O, Amigorena S (2002) Exosomes activate naive CD4+ T cells by transfer of MHC/peptide complexes to dendritic cells. Nat Immunol 3:1156–1162CrossRefPubMed

21.

Lamparski H, Metha-Damani A, Yao J, Patel S, Hsu D, Ruegg C, Le Pecq J (2002) Production and characterization of clinical grade exosomes derived from dendritic cells. J Immunol Meth 270(2):211

22.

H. Pêche (2001) Club Francophone Des Cellules Dendritiques, p 31 (Abstract C08)

23.

E. Angevin (2002) 7th International Symposium on Dendritic Cells, p 28 (Abstract 20)

Titel: Exosome-based immunotherapy
verfasst von: Nathalie Chaput
Julien Taïeb
Noël E. C. Schartz
Fabrice André
Eric Angevin
Laurence Zitvogel
Publikationsdatum: 01.03.2004
Verlag: Springer-Verlag
Erschienen in: Cancer Immunology, Immunotherapy / Ausgabe 3/2004
Print ISSN: 0340-7004
Elektronische ISSN: 1432-0851
DOI: https://doi.org/10.1007/s00262-003-0472-x

Springer Medizin

Exosome-based immunotherapy

Abstract

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 3/2004

A primer on cancer immunology and immunotherapy

Heat shock proteins: biological functions and clinical application as personalized vaccines for human cancer

Recombinant immunotoxins and retargeted killer cells: employing engineered antibody fragments for tumor-specific targeting of cytotoxic effectors

Dendritic cell biology and cancer therapy

The use of gene function to identify the rate-limiting steps controlling cell fate

Immunobiology of HER-2/neu oncoprotein and its potential application in cancer immunotherapy

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie